Adapting Biomarker Testing Practices as Targeted Therapies Shift to Earlier Lines of Treatment
Panelists discuss the prevalence of PIK3CA mutations in HR positive (HR+)/ HER2 negative (HER2-) breast cancer, their prognostic implications, and the critical role of identifying these mutations for personalized treatment planning, while Ms. Harrington shares insights on common patient questions about biomarker testing, the importance of molecular testing, and educational resources for helping patients understand their test results; Dr Kaklamani addresses how the approval of inavolisib may prompt routine PIK3CA mutation testing in the frontline setting, and Dr Isaacs and Ms. Diaz discuss the infrastructure changes needed in community practices to support this shift and the lessons learned from evolving biomarker testing practices.
Video content above is prompted by the following:
- Dr Kaklamani asks Dr Isaacs: As we transition to discussing biomarker testing, could you highlight the prevalence of PIK3CA mutations in HR+/HER2- breast cancer, their prognostic implications, and why identifying these mutations is crucial for treatment planning?
- Dr Kaklamani asks Ms. Harrington: From your experience working with patients, what questions do patients typically have about biomarker testing? How do you explain the importance of molecular testing and its implications for treatment decision-making?
- What resources and educational materials have you found most helpful in supporting patients through the biomarker testing process? How do you help patients understand the connection between their test results and treatment options?
- Dr Kaklamani addresses: With inavolisib's approval, how will you adapt your approach to biomarker testing? Do you anticipate the practice shifting to routinely testing for PIK3CA mutations in the frontline setting?
- Dr Kaklamani asks Dr Isaacs and Ms Diaz: What infrastructure changes might be needed in community practices to support routine frontline biomarker testing? What lessons have we learned in recent years as biomarker testing practices have evolved?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
